Oruba Presents State-of-the-Art Self-Operating Uroflowmeters
|
By LabMedica International staff writers Posted on 15 Nov 2023 |

Oruba Technology & Innovation (Langenfeld, Germany) is demonstrating its state-of-the-art self-operating uroflowmeters at MEDICA 2023.
Oruba is showcasing Oruflow, the world’s first self-operating uroflowmeter. As a point-of-care diagnostic device, it eases and accelerates the uroflowmetry process in a hygienic and comfortable atmosphere. The self-cleaning and hygienic point-of-care solution has revolutionized the process of uroflowmetry, making it a crucial part of every hospital and urology clinic. The self-operating uroflowmeter can be operated in easy steps. The patient first has to scan the hospital barcode to start the examination. The on-board screen helps the patients and guides them during the examination. Oruba Oruflow measures the test parameters and prepares the report. The patient then uses the hospital barcode to let Oruba Oruflow save the examination report into the hospital information system automatically. The patient can receive the results of the examination in seconds without any operator guidance.
As soon as the urination finishes, Oruba Oruflow prints the results out and cleans itself automatically. The patient can go to the doctor directly and the device gets ready for the next examination in one minute. Oruba Oruflow does not require an operator or nurse guidance and the patient does the test in an actual restroom comfort. Oruba Oruflow technology creates a hygienic and relaxed clinical atmosphere and prevents the unpleasant smell and dirt problem. Oruba Oruflow’s high-developed IoT technology and auto-notification system allows it to provide online technical service and solve the problem in minutes. The yearly maintenance and software upgrades are done from the Oruba HQ
Related Links:
Oruba Technology & Innovation
Latest Medica 2023 News
- Absology Showcases Latest Advancements in Medical Diagnostics
- Noul Showcases AI-Driven Blood and Cancer Diagnostic Platform
- Awareness Technology Exhibits Incredibly Flexible ChemWell 2 ELISA and Chemiluminescent Analyzer
- BioVendor Group Demonstrates Unique IVD Platform and Immunoblot Test
- Greiner Bio-One Highlights Magnetic 3D Cell Culture Technology
- Fujirebio Showcases Range of Novel Testing Solutions
- Sentinel Diagnostics Demonstrates New SENTiNAT 200 and STAT-NAT Kits for Infectious Diseases
- DiaSys Showcases High Quality Diagnostic Reagents and System Solutions
- Randox Exhibits Full Range of Molecular Diagnostic Solutions
- Alcor Scientific Demonstrates Fully-Automated ESR Analyzers
- Bosch Healthcare Presents Vivalytic Point-of-Care PCR System
- CerTest Presents Innovations Related to VIASURE Products
- Vircell Highlights All-in-One CLIA System and Real Time PCR Kits
- Tianlong Showcases Cutting-Edge Products and Innovative Molecular Diagnostic Solutions
- Getein Biotech Exhibits Advanced POCT Analyzers
- LumiraDx Demonstrates Transformative Tests and Technologies
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more









